Raia Drogasil (OTC: RADLY)

$3.37-5.07%today

Brazilian ADR trading on the OTC, priced in US dollars.

Display currency

Market Cap, EPS and the financial totals below — switch between US dollars and BRL.

Market Cap: $5.88B
P/E (TTM): 21.1x
P/B: 4.1x
EPS (TTM): $0.16
Dividend Yield: 2.51%
52-Week Range: $3.07 – $5.34
Volume: 22K
Previous Close: $3.55

TTM = trailing twelve months — the most recent 12 months (a rolling window), used for P/E, EPS and dividends. On the tables and charts below, the in-progress current year appears as a “Last 12M” column labelled with the quarter range it covers.

Performance

Today

-5.07%

1 Week

-11.78%

1 Month

-6.65%

YTD

-27.56%

1 Year

+5.74%

5 Years

-29.35%

About Raia Drogasil

US Ticker: RADLY
B3 Ticker: RADL3
Exchange: OTC
Currency: USD
Sector: Healthcare
Industry: Pharmaceutical Retailers
Headquarters: São Paulo, SP, Brazil
Employees: 75,594
CEO: Mr. Renato Cepollina Raduan
Founded: 1905

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil.

The company sells its products through stores, telesales, and call centers.

Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.

rdsaude.com.br

Analyst Ratings

Consensus of 1 Wall Street analyst · sourced from Yahoo Finance

None

On a 1–5 scale: 1 = Strong Buy, 3 = Hold, 5 = Sell. Lower is more bullish.

12-Month Price Target

Low

$5.40

Average

$5.40

High

$5.40

The average target is +60.24% above the current price of $3.37.

Financial Results

Revenue, EBITDA and net profit (in USD) with net margin (net profit ÷ revenue).

Financial Health

Margins, leverage and cash-flow quality derived from Raia Drogasil's income statement, balance sheet and cash flow (absolute figures in USD).

ProfitabilityLeverageGrowth

Overall: Financially Strong

Net Margin: 2.9%
ROE: 17.3%
Rev Growth (YoY): -1.00%
Net Debt / EBITDA: 1.98×
Current Ratio: 1.41×
Interest Coverage: 2.17×
Free Cash Flow: 262.8M
Payout Ratio: —

Income — Margins & Efficiency

Metric	Last 12MQ3'25 – Q2'26	Δ	2025	Δ	2024	Δ	2023	Δ	2022
Revenue	$8,466,015,614	+4.8%	$8,080,502,721	+28.4%	$6,292,028,359	-10.2%	$7,004,616,304	+27.3%	$5,500,393,596
Gross profit	$2,665,469,109	+12.6%	$2,367,497,170	+26.6%	$1,870,664,951	-11.1%	$2,104,524,350	+26.2%	$1,667,007,531
Operating income	$532,441,687	+10.1%	$483,725,028	+26.1%	$383,700,125	-4.7%	$402,734,733	+14.1%	$353,109,412
EBITDA	$788,148,105	+21.1%	$650,631,277	+27.9%	$508,859,807	-10.3%	$567,434,333	+22.3%	$464,102,865
Net profit	$243,959,650	+3.0%	$236,817,684	+21.9%	$194,218,747	-10.7%	$217,511,237	+15.4%	$188,493,358
Gross margin	31.5%	+2.2 p.p.	29.3%	-0.4 p.p.	29.7%	-0.3 p.p.	30.0%	-0.3 p.p.	30.3%
Operating margin	6.3%	+0.3 p.p.	6.0%	-0.1 p.p.	6.1%	+0.3 p.p.	5.7%	-0.7 p.p.	6.4%
EBITDA margin	9.3%	+1.3 p.p.	8.1%	-0.0 p.p.	8.1%	-0.0 p.p.	8.1%	-0.3 p.p.	8.4%
Net margin	2.9%	-0.0 p.p.	2.9%	-0.2 p.p.	3.1%	-0.0 p.p.	3.1%	-0.3 p.p.	3.4%
Revenue growth (YoY)	-1.0%	-14.8 p.p.	13.8%	-0.6 p.p.	14.4%	-2.5 p.p.	16.9%	—	—
Effective tax rate	11.9%	+1.7 p.p.	10.2%	-4.4 p.p.	14.6%	+4.0 p.p.	10.6%	-4.3 p.p.	14.9%
Interest coverage	2.17×	-8.1%	2.36×	-14.1%	2.75×	+3.7%	2.65×	-15.5%	3.13×

Newest column (“Last 12M”) = trailing 12 months, the last 4 reported quarters — shown with the quarter range it spans; earlier columns are full fiscal years.

Balance Sheet — Health & Leverage

Metric	Last 12MQ3'25 – Q2'26	Δ	2025	Δ	2024	Δ	2023	Δ	2022
Net debt	$1,556,908,420	+2.4%	$1,520,113,948	+30.6%	$1,163,901,164	-15.2%	$1,372,137,850	+28.9%	$1,064,294,554
Net Debt / Equity	1.11×	-2.8%	1.14×	+1.7%	1.12×	+0.0%	1.12×	+6.1%	1.05×
Net Debt / EBITDA	1.98×	-15.4%	2.34×	+2.1%	2.29×	-5.4%	2.42×	+5.4%	2.29×
Debt / Equity	1.18×	-2.3%	1.21×	+0.6%	1.20×	+1.1%	1.19×	+4.6%	1.13×
Current ratio	1.41×	-3.8%	1.46×	+5.8%	1.38×	-3.5%	1.43×	-4.9%	1.50×
Return on equity (ROE)	17.3%	-0.4 p.p.	17.7%	-0.9 p.p.	18.7%	+0.9 p.p.	17.7%	-0.9 p.p.	18.7%
Return on assets (ROA)	5.1%	-0.1 p.p.	5.2%	-0.3 p.p.	5.4%	+0.2 p.p.	5.3%	-0.5 p.p.	5.8%
Book value / share	$0.81	+7.4%	$0.75	+25.8%	$0.60	-15.1%	$0.70	+21.5%	$0.58

Newest column (“Last 12M”) = trailing 12 months, the last 4 reported quarters — shown with the quarter range it spans; earlier columns are full fiscal years.

Net Debt & Leverage

Free Cash Flow

Margins

Dividend Payout Ratio

Capex ÷ Revenue

Cash Conversion (operating cash flow ÷ net income)

Ratios computed from company financial statements. Net Debt = total debt − cash & equivalents; FCF = operating cash flow − capital expenditure; absolute values in USD.

Valuation & Dividends

P/E Ratio History

Dividend History

This year (YTD) $0.04/share · yield 1.16%

Dividends and yield from Yahoo Finance (per ADR share, in US dollars). The current-year figures are calendar year-to-date (dividends actually paid this year), not the trailing 12 months.

Listings

Raia Drogasil trades on 2 exchanges. Prices on this page are the OTC ADR (RADLY).

Exchange	Ticker	Currency
OTCpriced here	RADLY	USD
B3 (São Paulo)	RADL3	BRL

Frequently Asked Questions

Why hold Raia Drogasil RADLY ADR instead of local B3 RADL3 shares?

Buying directly on Brazil’s B3 exchange means opening a local brokerage account, converting currency and dealing with Brazilian tax paperwork. ADRs remove that friction: they settle in dollars, follow US market hours, and report in formats foreign investors already understand.

The trade-off is that an ADR’s price reflects two moving parts: (1) the underlying share price, quoted in reais on the B3, and (2) the USD/BRL exchange rate. Because of that second part, a rising company can still deliver a flat, or even negative, dollar return if the real weakens against the dollar. The same applies to ETFs: funds such as EWZ, EWZS and FLBR bundle dozens of these companies into a single ticker for instant diversification, but their dollar value still moves with the real.

Where is Raia Drogasil listed?

Raia Drogasil trades on 2 exchanges. The line quoted on this page is OTC in the United States (RADLY, US dollars). It also trades on B3 (São Paulo) in Brazil (RADL3, Brazilian reais).

On how many exchanges does Raia Drogasil trade?

2. OTC — RADLY (USD) · B3 (São Paulo) — RADL3 (BRL). Prices shown on this page are the OTC line, RADLY.

What is Raia Drogasil's primary listing?

Raia Drogasil's primary listing is on the B3 in Brazil, where the shares trade as RADL3 in reais — the company's home market. The OTC line quoted on this page is an ADR over those same shares: it gives you the asset in US dollars, on US market hours, without opening a Brazilian brokerage account or trading in reais.

What is the difference between RADLY and RADL3?

They are the same company and, economically, the same asset. RADL3 is the original Brazilian share, listed on the B3 and quoted in reais. RADLY is an American Depositary Receipt over that share, listed on the OTC and quoted in US dollars — a wrapper whose purpose is to give foreign investors access to the Brazilian asset without opening an account in Brazil. The RADLY price therefore tracks two things: RADL3 in reais, and the USD/BRL exchange rate.

How can I buy Raia Drogasil stock in the United States?

Raia Drogasil is listed on the OTC under RADLY, priced in US dollars. Any US brokerage offering over-the-counter securities can trade it, with no foreign-account paperwork and no currency conversion.

As of Fri, Aug 14, 17:00 BRT · Market closed

Financial data last updated: August 14, 2026

← All stocks & ETFs